JP2015527343A5 - - Google Patents

Download PDF

Info

Publication number
JP2015527343A5
JP2015527343A5 JP2015525636A JP2015525636A JP2015527343A5 JP 2015527343 A5 JP2015527343 A5 JP 2015527343A5 JP 2015525636 A JP2015525636 A JP 2015525636A JP 2015525636 A JP2015525636 A JP 2015525636A JP 2015527343 A5 JP2015527343 A5 JP 2015527343A5
Authority
JP
Japan
Prior art keywords
seq
carrier
cell
polypeptide
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525636A
Other languages
English (en)
Japanese (ja)
Other versions
JP6618360B2 (ja
JP2015527343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053493 external-priority patent/WO2014022811A1/en
Publication of JP2015527343A publication Critical patent/JP2015527343A/ja
Publication of JP2015527343A5 publication Critical patent/JP2015527343A5/ja
Application granted granted Critical
Publication of JP6618360B2 publication Critical patent/JP6618360B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525636A 2012-08-03 2013-08-02 薬物送達タンパク質の輸送向上変異体の単離 Expired - Fee Related JP6618360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679306P 2012-08-03 2012-08-03
US61/679,306 2012-08-03
PCT/US2013/053493 WO2014022811A1 (en) 2012-08-03 2013-08-02 Isolating traffic-enhancing mutants of drug delivery protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019132760A Division JP2020002138A (ja) 2012-08-03 2019-07-18 薬物送達タンパク質の輸送向上変異体の単離

Publications (3)

Publication Number Publication Date
JP2015527343A JP2015527343A (ja) 2015-09-17
JP2015527343A5 true JP2015527343A5 (enExample) 2016-09-15
JP6618360B2 JP6618360B2 (ja) 2019-12-11

Family

ID=50028570

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015525636A Expired - Fee Related JP6618360B2 (ja) 2012-08-03 2013-08-02 薬物送達タンパク質の輸送向上変異体の単離
JP2019132760A Pending JP2020002138A (ja) 2012-08-03 2019-07-18 薬物送達タンパク質の輸送向上変異体の単離

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019132760A Pending JP2020002138A (ja) 2012-08-03 2019-07-18 薬物送達タンパク質の輸送向上変異体の単離

Country Status (18)

Country Link
US (2) US10036009B2 (enExample)
EP (1) EP2880160B1 (enExample)
JP (2) JP6618360B2 (enExample)
KR (1) KR102115630B1 (enExample)
CN (1) CN104619839A (enExample)
AU (2) AU2013296218B2 (enExample)
BR (1) BR112015002004A2 (enExample)
CA (1) CA2881582A1 (enExample)
DK (1) DK2880160T3 (enExample)
ES (1) ES2703052T3 (enExample)
IL (1) IL236955A0 (enExample)
IN (1) IN2015DN01196A (enExample)
MX (1) MX366347B (enExample)
PL (1) PL2880160T3 (enExample)
PT (1) PT2880160T (enExample)
RU (1) RU2015105052A (enExample)
WO (1) WO2014022811A1 (enExample)
ZA (1) ZA201500739B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
MX2016013025A (es) 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439829A (en) 1991-01-30 1995-08-08 Eli Lilly And Company Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5547945A (en) 1993-07-15 1996-08-20 Jcr Pharmaceuticals Co., Ltd. Remitting agent for nephrotic syndrome and hepatopathy symptoms
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL124654A0 (en) 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
JP4515542B2 (ja) * 1997-02-10 2010-08-04 ジェネンテック， インコーポレイテッド ヒレグリン変異体
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
AU760766B2 (en) 1998-08-18 2003-05-22 Regents Of The University Of California, The Preventing airway mucus production by administration of EGF-R antagonists
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
CA2415319A1 (en) 2000-06-16 2001-12-20 Martek Biosciences Corporation Recombinant phycobiliprotein and phycobiliprotein linker fusion proteins and uses therefore
IT1318704B1 (it) * 2000-09-22 2003-08-27 Consorzio Interuniversitario P Vettori chimerici e loro uso per il trasferimento di geni eterologhi.
AU2002240201A1 (en) 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
EP1266963A1 (en) * 2001-06-15 2002-12-18 Crucell Holland B.V. Chimaeric phages
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20060014712A1 (en) 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
JP4479755B2 (ja) 2007-07-03 2010-06-09 ソニー株式会社 有機エレクトロルミネッセンス素子、及び、有機エレクトロルミネッセンス表示装置
US9078927B2 (en) * 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
CN101883858B (zh) * 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2682335C2 (ru) * 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
MX2016013025A (es) * 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
MX2018014576A (es) * 2016-05-27 2019-06-06 Cedars Sinai Medical Center Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.

Similar Documents

Publication Publication Date Title
JP2015527343A5 (enExample)
US11946040B2 (en) Adenine DNA base editor variants with reduced off-target RNA editing
EP4021945A2 (en) Combinatorial adenine and cytosine dna base editors
Yuan et al. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Bennett et al. Plasma membrane-targeted PIN proteins drive shoot development in a moss
Bourgeois et al. A highly characterized synthetic landing pad system for precise multicopy gene integration in yeast
David et al. A perspective on synthetic biology in drug discovery and development—current impact and future opportunities
IL263375A (en) Methods and preparations for integrating exogenous sequence into the genome of plants
JP2015525065A5 (enExample)
JP2018510628A5 (enExample)
RU2015105052A (ru) Выделение мутантов белка доставки лекарственного средства, усиливающих направленную миграцию
NZ723978A (en) Genes involved in noscapine production
JP2016537028A5 (enExample)
Taton et al. Heterologous expression of cryptomaldamide in a cyanobacterial host
JP2013530689A5 (enExample)
Zhu et al. Using defined finger–finger interfaces as units of assembly for constructing zinc-finger nucleases
Yuan et al. Manipulation of the global regulator mcrA upregulates secondary metabolite production in Aspergillus wentii using CRISPR-Cas9 with in vitro assembled ribonucleoproteins
JP2014527801A5 (enExample)
AR026571A1 (es) Genes del musgo de la physcomitrella patens que codifican proteinas que participan en la sintesis de los acidos grasos poliinsaturados y lipidos
JP2013530965A5 (enExample)
Gehrke et al. Current non-viral-based strategies to manufacture CAR-T cells
JP2015529629A5 (enExample)
CA2475276A1 (en) Zinc finger libraries
CN105999227A (zh) FOXM1蛋白氮端（1-234 aa）的表达及其用途
Millerioux et al. Development of a URA5 integrative cassette for gene disruption in the Candida guilliermondii ATCC 6260 strain